(Z)-des-A,B-8β-[(tert-butyldimethylsilyl)oxy]pregn-17(20)-ene | 502687-68-5

• 分子结构分类: 有机化合物 - 有机金属化合物 - 有机类金属化合物
• 英文名称: (Z)-des-A,B-8β-[(tert-butyldimethylsilyl)oxy]pregn-17(20)-ene
• 英文别名: tert-butyl{[(1Z,3aR,4S,7aS)-1-ethylidene-7a-methyloctahydro-1H-inden-4-yl]oxy}dimethylsilane；[(1Z,3aR,4S,7aS)-1-ethylidene-7a-methyl-3,3a,4,5,6,7-hexahydro-2H-inden-4-yl]oxy-tert-butyl-dimethylsilane
• CAS: 502687-68-5
• 化学式: C₁₈H₃₄OSi
• 分子量: 294.553
• InChiKey: PNDBEHUCPLMHFX-FSJOPXLVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.92
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (Z)-des-A,B-8β-[(tert-butyldimethylsilyl)oxy]pregn-17(20)-ene 在 吡啶 、 4-二甲氨基吡啶 、 氢氧化钾 、 重铬酸吡啶 、 正丁基锂 、 硼烷四氢呋喃络合物 、 dilithium tetrachlorocuprate 、 三氟化硼乙醚 、 magnesium 、 三乙胺 作用下， 以 四氢呋喃 、 吡啶 、 甲醇 、 正己烷 、 二氯甲烷 、 乙腈 为溶剂， 反应 98.55h， 生成 (5Z,7E)-(1R,3S)-1,3-bis[(tert-butyldimethylsilyl)oxy]-25-[(trimethylsilyl)oxy]-9,10-secocholesta-5,7,10(19)-trien-16α-yl hydrogen glutarate
  参考文献：
  名称：

  1alpha，25-dihydroxy-vitamin D3及其20-epi类似物的新型半抗原衍生物的合成。

  摘要：

  合成了1alpha，25-dihydroxyvitamin D（3）的Hapten衍生物及其20个受体，并将其缀合到载体蛋白上以产生多克隆抗体。半抗原通过在C-16处的间隔基连接，从而暴露分子的A环和侧链，以最大化抗体特异性。间隔基是通过16烯中间体的立体选择性硼氢化引入的，这是关键步骤。在免疫测定中，针对天然激素的抗体相对于具有A环或侧链修饰的衍生物对该化合物具有选择性。然而，针对20个末端的抗体不能识别侧链中的修饰。

  DOI：

  10.1021/jo026061s
• 作为产物：
  描述：

  (3aR,4S,7aS)-4-bromo-7a-methyloctahydro-1H-indene-1,5-dione 在 2,6-二甲基吡啶 、 lithium tri-t-butoxyaluminum hydride 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 1.5h， 生成 (Z)-des-A,B-8β-[(tert-butyldimethylsilyl)oxy]pregn-17(20)-ene
  参考文献：
  名称：

  Synthesis of Denosomin–Vitamin D₃ Hybrids and Evaluation of Their Anti-Alzheimer’s Disease Activities

  摘要：

  As an extension of previously conducted studies on developing an anti-Alzheimer's disease agent, denosomin (1-deoxy-24-norsominone, an artificial inducer of neurite elongation), derivatives were designed and synthesized based on the hypothesis that our denosomin would exhibit axonal extension activity via a 1,25D(3)-membrane-associated, rapid response steroid-binding protein (1,25D(3)-MARRS) pathway. The biological assay revealed that the hybridization of characteristic delta-lactone in denosomin and the triene moiety in VD3 was effective to enhance the nerve re-extension activity in amyloid beta (A beta)-damaged neurons.

  DOI：

  10.1021/acs.orglett.5b03138

文献信息

• VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING
  申请人：Von Geldern Thomas W.

  公开号：US20090131379A1

  公开（公告）日：2009-05-21

  The invention relates to compounds that are vitamin D receptor activators, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.

  该发明涉及一种维生素D受体激活剂化合物，包括这种化合物的组合物，使用这种化合物和组合物的方法，制备这种化合物的过程，以及在这些过程中获得的中间体。
• Synthesis and structure–activity relationships of 16-ene-22-thia-1α,25-dihydroxy-26,27-dimethyl-19-norvitamin D3 analogs having side chains of different sizes
  作者：Hajime Takaku、Yukiko Miyamoto、Shiori Asami、Mika Shimazaki、Sachiko Yamada、Keiko Yamamoto、Nobuyuki Udagawa、Hector F. DeLuca、Masato Shimizu

  DOI：10.1016/j.bmc.2007.11.013

  日期：2008.2.15

  We have synthesized eight novel 16-ene-22-thia-26,27-dimethyl-19-norvitamin D3 analogs 1-5 bearing side chains of different sizes, in combination with 20S- and 20R-isomers. The target compounds were prepared by Wittig-Horner reaction of A-ring phosphine oxide with 16-ene-22-thia-25-hydroxy Grundmann's ketones having different sized side chains, which were derived from the S-phenyloxycarbonyl derivative

  我们已经合成了八个带有不同大小侧链的16-ene-22-thia-26,27-二甲基-19-norvitamin D3类似物1-5，与20S和20R异构体结合在一起。通过A-环氧化膦与具有不同侧链尺寸的16-烯-22-噻-25-羟基格伦德曼酮的Wittig-Horner反应制备目标化合物，所述酮衍生自作为主要中间体的S-苯氧羰基衍生物13。研究了合成的22-thia-19-norvitamin D类似物1-5对维生素D受体（VDR）的结合亲和力，VDR介导的转录活性和破骨细胞诱导活性。就体外测试的生物学活性而言，（20S）-22-硫杂-19,24-地诺维生素D类似物1a与天然激素1α，25-二羟基维生素D3（1α，25-（OH）2D3）具有相同的活性。类似物2a和3a在与VDR的结合中表现出与1alpha，25-（OH）2D3几乎相同的效能，在转录活性方面比1alpha，25-（OH）2D
• Vitamin D receptor activators and methods of making
  申请人：Von Geldern Thomas W.

  公开号：US08377913B2

  公开（公告）日：2013-02-19

  The invention relates to compounds that are vitamin D receptor activators, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.

  本发明涉及一种维生素D受体激活剂化合物，包括该化合物的组合物、使用该化合物和组合物的方法、制备该化合物的方法以及在这些过程中获得的中间体。
• Synthesis of Denosomin–Vitamin D₃ Hybrids and Evaluation of Their Anti-Alzheimer’s Disease Activities
  作者：Kenji Sugimoto、Hisanari Yajima、Yusuke Hayashi、Daishiro Minato、Sayuri Terasaki、Chihiro Tohda、Yuji Matsuya

  DOI：10.1021/acs.orglett.5b03138

  日期：2015.12.4

  As an extension of previously conducted studies on developing an anti-Alzheimer's disease agent, denosomin (1-deoxy-24-norsominone, an artificial inducer of neurite elongation), derivatives were designed and synthesized based on the hypothesis that our denosomin would exhibit axonal extension activity via a 1,25D(3)-membrane-associated, rapid response steroid-binding protein (1,25D(3)-MARRS) pathway. The biological assay revealed that the hybridization of characteristic delta-lactone in denosomin and the triene moiety in VD3 was effective to enhance the nerve re-extension activity in amyloid beta (A beta)-damaged neurons.
• Synthesis of Novel Hapten Derivatives of 1α,25-Dihydroxy-vitamin D₃ and Its 20-Epi Analogue¹
  作者：Lars K. A. Blæhr,*、Fredrik Björkling、Martin J. Calverley、Ernst Binderup、Mikael Begtrup

  DOI：10.1021/jo026061s

  日期：2003.2.1

  Hapten derivatives of 1alpha,25-dihydroxyvitamin D(3) and its 20-epimer were synthesized and conjugated to a carrier protein for raising polyclonal antibodies. The haptens were linked through spacers at C-16, thereby exposing both the A-ring and the side chain of the molecules, to maximize antibody specificity. The spacers were introduced via stereoselective hydroboration of 16-ene intermediates as

  合成了1alpha，25-dihydroxyvitamin D（3）的Hapten衍生物及其20个受体，并将其缀合到载体蛋白上以产生多克隆抗体。半抗原通过在C-16处的间隔基连接，从而暴露分子的A环和侧链，以最大化抗体特异性。间隔基是通过16烯中间体的立体选择性硼氢化引入的，这是关键步骤。在免疫测定中，针对天然激素的抗体相对于具有A环或侧链修饰的衍生物对该化合物具有选择性。然而，针对20个末端的抗体不能识别侧链中的修饰。